Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Asger Bihlet"'
Autor:
Anne-Christine Bay-Jensen, Asger Bihlet, Inger Byrjalsen, Jeppe Ragnar Andersen, Bente Juhl Riis, Claus Christiansen, Martin Michaelis, Hans Guehring, Christoph Ladel, Morten A. Karsdal
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract The heterogeneous nature of osteoarthritis (OA) and the need to subtype patients is widely accepted in the field. The biomarker CRPM, a metabolite of C-reactive protein (CRP), is released to the circulation during inflammation. Blood CRPM le
Externí odkaz:
https://doaj.org/article/f2558c7d1f10478b8c5f1554b53e37d1
Autor:
Cecilie L. Bager, Morten Karsdal, Asger Bihlet, Christian Thudium, Inger Byrjalsen, Anne C. Bay-Jensen
Publikováno v:
BMC Musculoskeletal Disorders, Vol 20, Iss 1, Pp 1-6 (2019)
Abstract Background Osteoarthritis (OA) leads to joint failure and total joint replacement (TJR, either hip (H) or knee (K)). Worsening of pain and joint space narrowing are believed to be surrogates for joint failure; however, we hypothesize that TJ
Externí odkaz:
https://doaj.org/article/803bd5e56a53428a8643b17a89b19223
Autor:
Jeppe Ragnar, Andersen, Inger, Byrjalsen, Asger, Bihlet, Faidra, Kalakou, Hans Christian, Hoeck, Gitte, Hansen, Henrik Bo, Hansen, Morten Asser, Karsdal, Bente Juel, Riis
Publikováno v:
British journal of clinical pharmacology. 79(4)
The aim of this project was to perform an empirical evaluation of the impact of on site source data verification (SDV) on the data quality in a clinical trial database to guide an informed decision on selection of the monitoring approach.We used data
Autor:
Andersen, Jeppe Ragnar, von Sehested, Christoffer, Byrjalsen, Inger, Popik, Sara, Follin, Anne Bo, Bihlet, Asger Reinstrup
Publikováno v:
British Journal of Clinical Pharmacology; Jun2023, Vol. 89 Issue 6, p1756-1766, 11p
Autor:
Bager, Cecilie L.1 (AUTHOR) cba@nordicbio.com, Karsdal, Morten2 (AUTHOR), Bihlet, Asger2 (AUTHOR), Thudium, Christian2 (AUTHOR), Byrjalsen, Inger2 (AUTHOR), Bay-Jensen, Anne C.2 (AUTHOR)
Publikováno v:
BMC Musculoskeletal Disorders. 6/26/201/9, Vol. 20 Issue 1, p1-6. 6p. 1 Chart, 1 Graph.
Publikováno v:
Arthritis & Rheumatology; Oct2019 Supplement S1, Vol. 71, p1-5362, 5362p
Publikováno v:
Rheumatology International; Dec2019, Vol. 39 Issue 12, p2189-2191, 3p
Autor:
Andersen, Jeppe Ragnar, Byrjalsen, Inger, Bihlet, Asger, Kalakou, Faidra, Hoeck, Hans Christian, Hansen, Gitte, Hansen, Henrik Bo, Karsdal, Morten Asser, Riis, Bente Juel
Publikováno v:
British Journal of Clinical Pharmacology; Apr2015, Vol. 79 Issue 4, p660-668, 9p, 4 Charts
Autor:
Morten A. Karsdal, Asger Reinstrup Bihlet, Inger Byrjalsen, J.J. Bjerre-Bastos, Jeppe Ragnar Andersen
Publikováno v:
Saturday, 15 June 2019.
Background: Development of new disease-modifying drugs in OA (DMOADs) is complicated by heterogeneous study populations and insensitive endpoints of structural change and symptoms, and discordance between structural disease severity and reported symp
Autor:
C. Derne, Inger Byrjalsen, L. Delpy, Henning B. Nielsen, Jeppe Ragnar Andersen, D. Carrara, Asger Reinstrup Bihlet
Publikováno v:
Annals of the Rheumatic Diseases. 79:1735.1-1736
Background:Development of improved topical treatments of painful joints is warranted. A novel diclofenac sodium gel formulation, AMZ001, has been developed with the purpose of improving 1) The onset and duration of pain relief, and 2) The ease of use